SttStrtSPDRS&PUSHlthCareSelectSectETF

Gilead Completes Acquisition of Tubulis, Investing $3.15 Billion to Enhance Oncology Portfolio

Erasca and Merck Collaborate to Study ERAS-0015 Combined with KEYTRUDA for RAS-Mutant Solid Tumors

Eli Lilly Announces Positive Phase 3 Results for Retatrutide, Showing Significant Weight Loss in Obese Patients

Johnson & Johnson Partners with Abu Dhabi Health Services to Launch Global Open Surgical Intelligence Network

Eli Lilly's Retatrutide 12mg Dose Achieves 30.3% Average Weight Loss at 104 Weeks

Eli Lilly: Patients on Highest Dose of Retatrutide Achieve 28.3% Weight Loss

Johnson & Johnson's Nipocalimab Approved in China

J&J's Efgartigimod Alfa Approved by China NMPA for Generalized Myasthenia Gravis

Gilead Issues $3 Billion Senior Notes for General Corporate Purposes

National Advertising Review Board Refers Merck's Bravecto Dose Claim to FTC and FDA

Eli Lilly Acquires Engage Bio to Accelerate Non-Viral Gene Drug Development

Merck and Kailun Bio's Sac-TMT Succeeds in Phase III Endometrial Cancer Trial

CDD and Eli Lilly Collaborate to Integrate TuneLab AI Platform into CDD Vault

Trump Portfolio Precisely Trades UnitedHealth Before Medicare Policy Reversal

Harvest Portfolios Group Inc. Increases Stake in Abbott by 5.4% Amid Strong Earnings

Fideuram Intesa Sanpaolo Acquires 84,300 JNJ Shares Worth $17.4M in Q4

Eli Lilly and Company announces an additional $4.5 billion investment in its Indiana manufacturing sites

Eli Lilly and Novo Nordisk are preparing to launch high-dose obesity treatments in the South Korean market

Financial disclosure reveals Donald Trump invested in Eli Lilly in Q1 2026, coinciding with the government's push for favorable weight-loss drug policies.

UnitedHealth Group Faces Profit Pressure Amid Rising Medical Costs and Membership Structure Changes

Co-Diagnostics

NewGenIvf

Liminatus Pharma

Agape ATP

Netcapital

Tradr 2X Long QBTS Daily ETF

Tradr 2X Long RGTI Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Sunshine Biopharma

PicoCELA

159898

SSEHF

The healthcare sector has emerged as a reliable source of job growth in the US, adding 76,000 jobs in March alone, according to the Bureau of Labor Statistics. This growth is driven by an aging population and rising chronic illnesses, with healthcare consistently adding jobs since January 2022. However, challenges such as rising costs and potential policy changes may threaten this stability. Experts warn that financial pressures could lead to workforce reductions and consolidation within the industry, despite the ongoing demand for healthcare services.

Invezz

Invesco Biotechnology & Genome ETF

VG Health

China Merchants CSI All Share Medical Apparatus and Instruments ETF

E Fund CSI 300 Health Care ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

iShares US Pharma

iShares US Medical Devices

iShares Global Healthcare

iShares Genomics Immunology and Healthcare ETF

SPDR S&P Biotech

SPDR S&P Health

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ALPS Medical Breakthrough

iShares US Healthcare

iShares Biotechnology ETF

SPDR S&P Health Equip

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

iShares US Healthcare Providers

Health Care Select Sector SPDR

ChinaAMC CSI All Share Health Care Devices ETF

Proshares UltraShort Nasdaq Biotech

How healthcare became the most reliable source of paychecks in the US

Medicare Advantage's growth has slowed in 2026, with 35.5 million enrollees, a 3.2% increase from 2025, down from previous annual growth rates of 7-10%. Plans are exiting unprofitable markets and trimming benefits due to rising medical costs and changes in government payments. The forced disenrollment rate has surged, with 1 in 10 enrollees needing to switch plans. Major insurers are reducing offerings, attributing changes to financial performance and federal policy adjustments. Despite the slowdown, Medicare Advantage is projected to control 64% of the market by 2034, as the overall Medicare market continues to grow.

Dow Jones

State Street®HlthCrSelSectSPDR®PrmETF

Medicare Advantage's once-blistering growth dropped in 2026. Here's what that means.

This article discusses exchange-traded funds (ETFs) that provide exposure to Europe's leading healthcare companies, including Novo Nordisk, Novartis, Sanofi, and Siemens. It highlights the cost-effectiveness of ETFs compared to purchasing individual stocks. Recommended ETFs include the iShares MSCI Europe Health Care Sector ETF (ESIH), MSCI Europe Health Care Screened ETF (XSDR), and SPDR MSCI Europe Health Care ETF (HLTH), which track various European healthcare companies and offer low expense ratios.

Tip Ranks

NOVARTIS AG

Sanofi

Novo Nordisk AS

Novartis AG

Defiance Daily Target 2X Long NVO ETF

Siemens

Siemens AG

Deutsche Bank AG

ESIH, XSDR, HLTH: These ETFs Provide Exposure to Europe's Top Healthcare Companies

SPEU

European equities traded in the US saw a rise in American depositary receipts, increasing 0.49% to 1,744.86 on the S&P Europe Select ADR Index. Notable gainers included BioNTech (+4.8%) and Equinor (+2.6%), while decliners included Novo Nordisk (-3.3%) and Ascendis Pharma (-2.2%). From the UK and Ireland, Silence Therapeutics led with a 7.9% increase, while Mereo BioPharma Group dropped 7.3%.

fidelity

SPDR Portfolio Europe ETF

BioNTech SE

Ascendis Pharmac

Invesco Nasdaq Biotechnology ETF

Equinor Asa

Silence Therapeutics

Mereo Biopharma

Equinor ASA

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

SttStrtSPDRS&PUSHlthCareSelectSectETF(SSEHF.US)

How healthcare became the most reliable source of paychecks in the US

Medicare Advantage's once-blistering growth dropped in 2026. Here's what that means.

ESIH, XSDR, HLTH: These ETFs Provide Exposure to Europe's Top Healthcare Companies

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading